Latigo Biotherapeutics Announces Plans for Nasdaq IPO to Fund Non-Opioid Pain Drug Development

Latigo Biotherapeutics, a Westlake BioPartners spin‑out founded in 2018, said it will seek a Nasdaq listing under the ticker LTGO.

The company develops non‑opioid analgesics that block sodium ion channels, with its lead candidate LTG‑101 slated to enter late‑stage trials by year‑end for moderate to severe acute pain.

Since its inception Latigo has raised about $322 million, but as of March 31 reported a cumulative deficit of $266 million and a $109 million net loss for 2025.

The filing adds Latigo to a wave of biotech IPOs this month and places it among a small group targeting sodium‑channel pain therapies, a space recently entered by Eli Lilly through its acquisition of SiteOne Therapeutics.